title: IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma.
abstract: To assess the expression of IGF-1R in oral cavity squamous cell carcinoma patients, to explore its relation with clinical and pathologic prognostic factors and its role in predicting clinical outcome. One hundred and thirty-one consecutive patients suffering from oral cavity squamous cell carcinoma were included in this study from July 1989 to April 2005. Follow-up was closed in May 2010. The mean follow-up for survivors was 110.26±47.42 months. Patients were staged following the TNM classification. Patients in tumour stages I and II were referred to surgery. Patients in stages III-IV were referred to postoperative radiotherapy. Radiation therapy was administered up to a mean dose of 62.13±7.74 Gy in 1.8-2 Gy fractions. IGF-1R expression was studied by immunohistochemistry in paraffin-embedded tumour tissue. IGF-1R was expressed in 101 patients (77.1%). IGF-1R expression was related to tumour grade (P=0.012). Tumour stage was the most important prognostic factor for survival. Low (negative and fairly) IGF-1R tumour expression was correlated to better long-term Local Disease Free Survival (P=0.016), Disease-Free Survival (P=0.029), and Survival (P=0.009) in patients achieving tumour stages III-IV. Low IGF-1R expression was related to better long-term control in patients suffering locally advanced oral carcinoma.
authors.affiliation: Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Spain.
authors.forename: Pedro C
authors.initials: PC
authors.lastname: Lara
authors.forename: Elisa
authors.initials: E
authors.lastname: Bordón
authors.forename: Agustín
authors.initials: A
authors.lastname: Rey
authors.forename: Mercedes
authors.initials: M
authors.lastname: Moreno
authors.forename: Marta
authors.initials: M
authors.lastname: Lloret
authors.forename: Luis Alberto
authors.initials: LA
authors.lastname: Henríquez-Hernández
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017526:Receptor, IGF Type 1